294 related articles for article (PubMed ID: 37938933)
21. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection.
Chang X; Wang J; Chen Y; Long Q; Song L; Li Q; Liu H; Shang Q; Yu Z; Jiang L; Xiao G; Li L; Chen L; Wang X; Li Z; Chen D; Dong Z; An L; Tan L; Chen Y; Yang Y
EBioMedicine; 2021 May; 67():103389. PubMed ID: 34004423
[TBL] [Abstract][Full Text] [Related]
22. Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.
Hu J; Zhang X; Gu J; Yang M; Zhang X; Zhao H; Li L
Eur J Gastroenterol Hepatol; 2019 Jul; 31(7):817-823. PubMed ID: 30543572
[TBL] [Abstract][Full Text] [Related]
23. Clinical noninvasive markers for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase less than two times upper limit of normal.
Wu Z; Dong X; Wang G; Zhao H;
J Viral Hepat; 2019 Feb; 26(2):287-296. PubMed ID: 30380162
[TBL] [Abstract][Full Text] [Related]
24. Comparative evaluation of GPR versus APRI and FIB-4 in predicting different levels of liver fibrosis of chronic hepatitis B.
Liu DP; Lu W; Zhang ZQ; Wang YB; Ding RR; Zhou XL; Huang D; Li XF
J Viral Hepat; 2018 May; 25(5):581-589. PubMed ID: 29230907
[TBL] [Abstract][Full Text] [Related]
25. Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.
Kim MN; Lee JH; Chon YE; Ha Y; Hwang SG
Eur J Gastroenterol Hepatol; 2020 Mar; 32(3):433-439. PubMed ID: 31490417
[TBL] [Abstract][Full Text] [Related]
26. Value of gamma-glutamyltranspeptidase-to-platelet ratio in diagnosis of hepatic fibrosis in patients with chronic hepatitis B.
Hu YC; Liu H; Liu XY; Ma LN; Guan YH; Luo X; Ding XC
World J Gastroenterol; 2017 Nov; 23(41):7425-7432. PubMed ID: 29151696
[TBL] [Abstract][Full Text] [Related]
27. The gamma-glutamyl transpeptidase-to-albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients.
Li Q; Lu C; Li W; Huang Y; Chen L
J Viral Hepat; 2017 Dec; 24(12):1143-1150. PubMed ID: 28685907
[TBL] [Abstract][Full Text] [Related]
28. A novel index using routine clinical parameters for predicting significant liver inflammation in chronic hepatitis B.
Wang J; Xia J; Zhang R; Yan X; Yang Y; Zhao X; Chang H; Wang G; Chen G; Liu Y; Chen Y; Jia B; Zhang Z; Ding W; Huang R; Wu C
J Viral Hepat; 2018 Oct; 25(10):1151-1160. PubMed ID: 29741221
[TBL] [Abstract][Full Text] [Related]
29. Correlation of liver biochemistry with liver stiffness in chronic hepatitis B and development of a predictive model for liver fibrosis.
Fung J; Lai CL; Fong DY; Yuen JC; Wong DK; Yuen MF
Liver Int; 2008 Dec; 28(10):1408-16. PubMed ID: 18482268
[TBL] [Abstract][Full Text] [Related]
30. A novel non-invasive model for the prediction of advanced liver fibrosis in chronic hepatitis B patients with NAFLD.
Wang J; Huang R; Liu J; Lai R; Liu Y; Zhu C; Qiu Y; He Z; Yin S; Chen Y; Yan X; Ding W; Zheng Q; Li J; Wu C
J Viral Hepat; 2023 Apr; 30(4):287-296. PubMed ID: 36696366
[TBL] [Abstract][Full Text] [Related]
31. The diagnostic value of non-invasive tests for the evaluation of liver fibrosis in chronic hepatitis B patients.
Erdogan S; Dogan HO; Sezer S; Uysal S; Ozhamam E; Kayacetin S; Koca Y
Scand J Clin Lab Invest; 2013; 73(4):300-8. PubMed ID: 23514016
[TBL] [Abstract][Full Text] [Related]
32. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response.
Shen Y; Wu SD; Chen Y; Li XY; Zhu Q; Nakayama K; Zhang WQ; Weng CZ; Zhang J; Wang HK; Wu J; Jiang W
Gut Microbes; 2023; 15(1):2155018. PubMed ID: 36519342
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathologic characteristics of liver inflammation and fibrosis in 310 patients with chronic hepatitis B.
Jiang C; Liu J; Li R; Chen K; Peng W; Fu L; Peng S
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 May; 48(5):698-706. PubMed ID: 37539572
[TBL] [Abstract][Full Text] [Related]
34. Comparison and evaluation of non-invasive models in predicting liver inflammation and fibrosis of chronic hepatitis B virus-infected patients with high hepatitis B virus DNA and normal or mildly elevated alanine transaminase levels.
Wang L; Li J; Yang K; Zhang H; Wang Q; Lv X; Guan S
Medicine (Baltimore); 2020 Jun; 99(23):e20548. PubMed ID: 32502018
[TBL] [Abstract][Full Text] [Related]
35. Diagnostic accuracy of APRI and FIB-4 for predicting hepatitis B virus-related liver fibrosis accompanied with hepatocellular carcinoma.
Xiao G; Zhu F; Wang M; Zhang H; Ye D; Yang J; Jiang L; Liu C; Yan L; Qin R
Dig Liver Dis; 2016 Oct; 48(10):1220-6. PubMed ID: 27599803
[TBL] [Abstract][Full Text] [Related]
36. Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication.
Jiang SW; Lian X; Hu AR; Lu JL; He ZY; Shi XJ; Zhu DD; Wang ZY; Huang GC
World J Gastroenterol; 2023 Apr; 29(16):2479-2494. PubMed ID: 37179582
[TBL] [Abstract][Full Text] [Related]
37. The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.
Li Q; Lu C; Li W; Huang Y; Chen L
Oncotarget; 2017 Apr; 8(17):28641-28649. PubMed ID: 28415736
[TBL] [Abstract][Full Text] [Related]
38. Serum ceruloplasmin levels correlate negatively with liver fibrosis in males with chronic hepatitis B: a new noninvasive model for predicting liver fibrosis in HBV-related liver disease.
Zeng DW; Liu YR; Zhang JM; Zhu YY; Lin S; You J; Li YB; Chen J; Zheng Q; Jiang JJ; Dong J
PLoS One; 2013; 8(10):e77942. PubMed ID: 24282481
[TBL] [Abstract][Full Text] [Related]
39. Liver stiffness-based optimization of hepatocellular carcinoma risk score in patients with chronic hepatitis B.
Wong GL; Chan HL; Wong CK; Leung C; Chan CY; Ho PP; Chung VC; Chan ZC; Tse YK; Chim AM; Lau TK; Wong VW
J Hepatol; 2014 Feb; 60(2):339-45. PubMed ID: 24128413
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of APRI and FIB-4 for noninvasive assessment of significant fibrosis and cirrhosis in HBeAg-negative CHB patients with ALT ≤ 2 ULN: A retrospective cohort study.
Li Q; Ren X; Lu C; Li W; Huang Y; Chen L
Medicine (Baltimore); 2017 Mar; 96(12):e6336. PubMed ID: 28328813
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
